A comparison of complex sleep behaviors with two short-acting Z-hypnosedative drugs in nonpsychotic patients

Li-Fen Chen1
Ching-En Lin1–3
Yu-Ching Chou4
Wei-Chung Mao1,5
Yi-Chyan Chen1–3
Nian-Sheng Tzeng1,6

1Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei City, Taiwan; 2Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, Taipei, Taiwan; 3School of Medicine, Tzu Chi University, Hualien, Taiwan; 4School of Public Health, National Defense Medical Center, Taipei City, Taiwan; 5Institute of Brain Science, School of Medicine, National Yang-Ming University, Taipei City, Taiwan; 6Student Counseling Center, National Defense Medical Center, Taipei City, Taiwan

Objective: Complex sleep behaviors (CSBs) are classified as “parasomnias” in the International Classification of Sleep Disorders, Second Edition (ICSD-2). To realize the potential danger after taking two short-acting Z-hypnosedative drugs, we estimated the incidence of CSBs in nonpsychotic patients in Taiwan.

Methods: Subjects (N = 1,220) using zolpidem or zopiclone were enrolled from the psychiatric outpatient clinics of a medical center in Taiwan over a 16-month period in 2006–2007. Subjects with zolpidem (N = 1,132) and subjects with zopiclone (N = 88) were analyzed. All subjects completed a questionnaire that included demographic data and complex sleep behaviors after taking hypnotics.

Results: Among zolpidem and zopiclone users, 3.28% of patients reported incidents of somnambulism or amnesic sleep-related behavior problems. The incidence of CSBs with zolpidem and zopiclone were 3.27%, and 3.41%, respectively, which was significantly lower than other studies in Taiwan.

Conclusion: These results serve as a reminder for clinicians to make inquiries regarding any unusual performance of parasomnic activities when prescribing zolpidem or zopiclone.

Keywords: parasomnia, somnambulism, amnesic sleep-related behavior, sleepwalking, zolpidem, zopiclone

Introduction
Complex sleep behaviors (CSBs) are complex activities, normally associated with wakefulness, that occur when the subject is in a sleep-like state after taking a hypnosedative drug; when the subject awakens the next morning, the subject has little or no memory of the activity. CSBs include sleepwalking with object manipulation,1,2 sleep-related eating disorders,3,4 and sexual assault.5 These behaviors may not occur frequently, but clinical awareness of the potential for associated danger and harm is necessary. CSBs induced by hypnosedatives have been the focus of much attention, especially after the US Food and Drug Administration requested in March 2007 that manufacturers of 13 kinds of hypnosedative drugs modify their product labeling to include new safety warnings about these potentially dangerous behaviors.6

Zolpidem, a nonbenzodiazepine receptor agonist, is a highly effective hypnotic with a short half-life, minimal daytime residual side effects at the recommended dose, a low risk for tolerance, dependence, or abuse,7,8 a low rate (1.1%) of adverse events, and no life-threatening events.9 Zolpidem does cause decreased rapid eye movement sleep while increasing total sleep time. Incidents of zolpidem-associated nocturnal wandering and abnormal sleep behavior have previously been reported as rare side effects.10
Zopiclone, also a nonbenzodiazepine hypnotic with even greater addictive potential than benzodiazepines, has been described as a “benzodiazepine in disguise”.\textsuperscript{11–13} It is thought to act on the GABA\textsubscript{A} receptor complex at a site distinct from the benzodiazepine binding site.\textsuperscript{14} Tolerance to the effects of zopiclone can develop after a few weeks’ use and abrupt withdrawal, particularly with prolonged and high doses. Zopiclone can also cause seizures and delirium.\textsuperscript{15,16} It is the first cyclopyrrolone possessing a pharmacological profile of high efficacy and low toxicity similar to that of benzodiazepines.\textsuperscript{17} Its elimination half-life is 5–6 hours, it does not accumulate upon repeated administration, and its pharmacokinetic profile is not substantially modified in the elderly and renal failure patients.\textsuperscript{18} In clinical trials, zopiclone (usually 7.5 mg) improved sleep in chronic insomniacs similarly to nitrazepam 5 mg, flurazepam 15–30 mg, triazolam 0.5 mg, and temazepam 20 mg, but in a single study was slightly less effective than flunitrazepam 2 mg in some evaluation criteria.\textsuperscript{17} The drug is generally well tolerated by patients of all ages and the most frequently reported adverse effects are bitter taste and dry mouth.\textsuperscript{14} Treatment for withdrawal due to adverse effects is seldom required and reports of rebound insomnia after zopiclone withdrawal are rare.\textsuperscript{14} Minimal impairment of psychomotor skills and mental acuity may occur in the morning after a bedtime dose of zopiclone.\textsuperscript{17}

Methods
In this study, we employed a case-control design to address the issue of CSBs in nonbenzodiazepine users. Specifically, we were most interested in testing whether medication, sex, and age would be risk predictors for CSBs.

Data were collected through extensive chart reviews of nonpsychotic outpatients treated with zolpidem or zopiclone for insomnia at psychiatric services of Tri-Service General Hospital (Taipei City, Taiwan) over a 16-month period in 2006–2007. Those who developed adverse side effects were included for further interviews. The inclusion criteria were: (1) 18–86 years of age; (2) prescribed zolpidem or zopiclone; (3) diagnosed with affective disorders, anxiety disorders, or simple sleep disturbance; and (4) cohabited with others, such as a family member or partner. Exclusion criteria were living alone, also taking benzodiazepines at night, or history of eating disorders, mental retardation, dementia, attention-deficit/hyperactivity disorders, substance abuse, and/or seizure disorders.

A total of 1,220 patients were eligible for the study (486 males, 734 females). All of the patients were taking hypnotic medications after evaluation and diagnosis by a psychiatrist on the basis of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision criteria. The patients were then given a structured interview by a trained assistant with a special focus on the quality of sleep and associated complaints after zolpidem or zopiclone use. Data on the patients’ demographic and personal history, including age, sex, drug category, and diagnosis, were recorded.

Statistical analysis
Descriptive results of continuous variables were expressed as mean (standard deviation) and categorical variables were expressed as frequency (%). All statistical analyses were performed with Student’s t-test, chi-square tests, and/or Fisher’s exact test using the Statistical Package for Social Sciences version 20.0 (SPSS, Inc, Chicago, IL, USA). A $P < 0.05$ was considered statistically significant.

Results
Among 1,220 zolpidem or zopiclone users, 40 (3.28%) patients reported incidents of somnambulism or amnesic sleep-related behavior problems. Seventeen subjects were male and 23 were female. The average age was 39.16 years, and the average dosage of zolpidem/zopiclone was 10.0 mg per day. The five most common diagnoses were: major depressive disorder, recurrent; dysthymic disorder; major depressive disorder, single episode; insomnia; and bipolar disorder. The behavioral problems included 20 patients who could not remember what happened after taking zolpidem/zopiclone. Among them, eleven ate food, four walked in their houses, two talked with others, and three had other symptoms such as dizziness (Table 1). There was no significant association with older age ($>65$ years), sex, side effects, or drug category, although those who had side effects were younger than those without side effects (34.20 years versus 39.33 years, $P = 0.033$) (Table 2).

Discussion
CSBs are categorized as “parasomnias” in the International Classification of Sleep Disorders (ICSD-2), which defines parasomnia as a sleep disturbance characterized primarily by undesirable physical events or experiences that occur during entry into sleep, within sleep, or during arousal from sleep.\textsuperscript{19} The incidence, mechanisms, and management of CSBs have been reported,\textsuperscript{20} especially for zolpidem-induced amnesia and somnambulism.\textsuperscript{21} The only unique risk predictor of zolpidem-related CSBs was a high dosage of zolpidem...
Table 1 Demographic data and complex sleep behaviors

| Variables       | Number | Percentage |
|-----------------|--------|------------|
| Age             |        |            |
| Mean ± SD (range) | 39.16 ± 14.98 | 18-86      |
| Sex             |        |            |
| Male            | 486    | 39.84      |
| Female          | 734    | 60.16      |
| Category        |        |            |
| Zopiclone       | 88     | 7.21       |
| Zolpidem        | 1132   | 92.79      |
| Side effects    |        |            |
| Without side effects | 1180 | 96.72      |
| Total with side effects | 40  | 3.28       |
| Eating during the night | 11 | 0.90       |
| Excitement/talkativeness | 2 | 0.16       |
| Somnambulism    | 4      | 0.33       |
| Antergrade amnesia | 20  | 1.64       |
| Others, such as dizziness | 3  | 0.25       |

Abbreviation: SD, standard deviation.

(>10 mg/day).\(^{22}\) However, comparisons of short-acting hypnotics are limited in Taiwan. We performed a chart review study for zolpidem and zopiclone in order to determine the incidence and risk factors for Z-drug-related CSBs.

A possible mechanism for hypnosedative CSBs and amnesia is enhanced GABA activity at GABA\(_{\alpha}\) receptors, especially the \(\alpha_1\)-GABA\(_{\alpha}\) receptors. The amnesia that accompanies CSBs is possibly due to inhibition of the consolidation of short- to long-term memory, suggesting that the risk may extend to non-GABAergic effects as well. While amnesia and GABA-related receptor actions are the most frequently discussed mechanisms for CSBs in the literature, they do not fully explain such behaviors. This suggests that other mechanisms and factors play a role.

In comparison with the data of Hwang et al\(^{22}\) and Tsai et al,\(^{21}\) our investigation focused on adverse reactions to zolpidem and zopiclone in nonpsychotic Taiwanese patients. For zolpidem, our study included 1,132 patients, which was 4.4–9.1 times larger than samples in the previous two articles. For zopiclone, our study included 88 patients; the previous two articles did not study zopiclone. The incidence of CSBs with these two short-acting Z-drugs was 3.28%, which was lower than the 5.1% reported by Tsai et al or the 15.2% reported by Hwang et al.\(^{21,22}\) We suggest that the main causes for the difference is our study’s larger patient sample size, removal of psychotic patients, and collecting data from outpatients treated by different attending physicians.

Conclusion

Although mean age of those with CSBs was younger than those without CSBs in our study, clinicians should still be cautious when prescribing “Z-drugs” in the treatment of elderly patients with sleep problems. Despite the lower incidence of CSBs shown in our study compared to previous studies, careful attention when prescribing these short-acting Z-drugs is still advised. Much more severe adverse effects have been reported for zolpidem or other nonbenzodiazepine hypnotics, such as falls in hospitalized patients\(^{23}\) or even hip fracture in nursing home residents.\(^{24}\) The relationship between zolpidem- or zopiclone-related CSBs and falls and hip fracture remains unclear, but is important to clarify in future studies.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Sharma A, Dewan VK. A case report of zolpidem-induced somnambulism. Prim Care Companion J Clin Psychiatry. 2005;7(2):74.
2. Yang W, Doller M, Muthukrishnan SR. One rare side effect of zolpidem – sleepwalking: a case report. Arch Phys Med Rehabil. 2005;86(6):1265–1266.
3. Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med. 2002;3(4):323–327.
4. Siddiqui F, Osuna E, Chokroverty S. Writing emails as part of sleepwalking after increase in Zolpidem. Sleep Med. 2009;10(2):262–264.
5. Kintz P, Villain M, Dumestre-Toilet V, Ludes B. Drug-facilitated sexual assault and auditory toxicology: the role of LC-MS/MS. A case involving zolpidem. J Clin Forensic Med. 2005;12(1):36–41.
6. US Food and Drug Administration. FDA requests label change for all sleep disorder drug products [press release]. Silver Spring, MD: US Food and Drug Administration [April 10, 2013]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108868.htm. Accessed July 16, 2013.
7. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59(4):865–889.
8. Soyka M, Bottlender R, Möller HJ. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry. 2000;33(4):138–141.
9. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol. 1998;13(4):157–167.
10. Tsai JH, Yang Pinchen, Chen CC, et al. Zolpidem-induced amnesia and somnambulism: Rare occurrences? Eur Neuropsychopharmacol. 2008;19(1):74–76.

Table 2 Differential analysis by age, sex, drug category, and side effects of patients

| Group       | Sample size (n) | Mean (age) | Standard deviation | P-value |
|-------------|----------------|------------|--------------------|---------|
| Male        | 486            | 36.54      | 15.47              | <0.001  |
| Female      | 734            | 40.90      | 14.40              |         |
| Zopiclone   | 88             | 38.58      | 14.62              | 0.704   |
| Zolpidem    | 1132           | 39.21      | 15.01              |         |
| Without side effects | 1180  | 39.33      | 14.99              | 0.033   |
| With side effects | 40     | 34.20      | 13.86              |         |
11. Luty S, Sellman D. Imovane – a benzodiazepine in disguise. NZ Med J. 1993;106(959):293.
12. Bramness JG, Olsen H. Adverse effects of zopiclone. Tidsskr Nor Laegeforen. 1998;118(13):2029–2032. Norwegian [with English abstract].
13. Deveaux M, Chêze M, Pépin G. The role of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to test blood and urine samples for the toxicological investigation of drug-facilitated crimes. Ther Drug Monit. 2008;30(2):225–228.
14. Wadworth AN, McTavish D. Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging. 1993;3(5):441–459.
15. [No authors listed]. Hypnotic dependence: zolpidem and zopiclone too. Prescrire Int. 2001;10(51):15.
16. Wong CP, Chiu PK, Chu LW. Zopiclone withdrawal: an unusual cause of delirium in the elderly. Age Ageing. 2005;34(5):526–527.
17. Goa KL, Heel RC. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic as an hypnotic. Drugs. 1986;32(1):48–65.
18. Musch B, Maillard F. Zopiclone, the third generation hypnotic: a clinical overview. Int Clin Psychopharmacol. 1990;5 Suppl 2:147–158.
19. American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed. Chicago: American Academy of Sleep Medicine; 2005.
20. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs. 2008;22(12):1021–1036.
21. Tsai JH, Yang P, Chen CC, et al. Zolpidem-induced amnesia and somnambulism: rare occurrences? Eur Neuropsychopharmacol. 2009;19:74–76.
22. Hwang TJ, Ni HC, Chen HC, Lin YT, Liao SC. Risk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study. J Clin Psychiatry. 2010;71(10):1331–1335.
23. Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med. 2013;8(1):1–6.
24. Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013;173(9):754–761.